Expand all sections

Human normal immunoglobulin

HyQvia

Extended indication Extension of indication to include treatment of Chronic Inflammatory Demyelinating Polyneuropathy (C
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Human normal immunoglobulin
Domain Neurological disorders
Reason of inclusion Indication extension
Main indication Neurological disorders other
Extended indication Extension of indication to include treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in adults.
Proprietary name HyQvia
Manufacturer Takeda
Route of administration Subcutaneous
Therapeutical formulation Injection
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Submission date February 2023
Expected Registration December 2023
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.